The next gen­er­a­tion of AI biotechs is here. Can they de­liv­er on the hype?

“We’re in a frothy time,” ac­knowl­edges Alexan­dra Sny­der, the head of R&D at Gen­er­ate:Bio­med­i­cines.

Gen­er­ate is one of the AI-dri­ven biotechs that make up a new gen­er­a­tion of com­pa­nies with huge fund­ing, A-list sci­ence and tech stars and com­put­ing horse­pow­er. On Tues­day, the $1 bil­lion-plus launch of Xaira Ther­a­peu­tics — the sec­ond-biggest ini­tial biotech start­up fund­ing ever — took a field that’s al­ready de­scribed by some as over­hyped and whipped it in­to a fren­zy.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER